Q3 2022 EPS Estimates for Pharming Group Cut by Oppenheimer (NASDAQ:PHAR)
Q3 2022 EPS Estimates for Pharming Group Cut by Oppenheimer (NASDAQ:PHAR)
Pharming Group (NASDAQ:PHAR – Get Rating) – Oppenheimer cut their Q3 2022 earnings per share estimates for Pharming Group in a report issued on Friday, August 5th. Oppenheimer analyst H. Singh now anticipates that the company will earn $0.00 per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Pharming Group's current full-year earnings is $0.02 per share. Oppenheimer also issued estimates for Pharming Group's FY2023 earnings at $0.01 EPS and FY2026 earnings at $0.05 EPS.
輝瑞集團(納斯達克：PharGet評級)-奧本海默在8月5日(星期五)發佈的一份報告中下調了Pharming Group 2022年第三季度每股收益預期。奧本海默分析師H·辛格現在預計，該公司本季度每股收益將為0.00美元，低於此前預測的0.01美元。對Pharming Group目前全年收益的普遍估計是每股0.02美元。奧本海默還發布了對Pharming Group 2023財年每股收益為0.01美元和2026財年每股收益為0.05美元的預期。
Pharming Group (NASDAQ:PHAR – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported $0.05 EPS for the quarter. The company had revenue of $46.62 million during the quarter, compared to analysts' expectations of $48.00 million.
輝瑞集團(納斯達克：PharGet Rating)最近一次發佈季度收益數據是在5月12日(星期四)。該公司公佈本季度每股收益為0.05美元。該公司當季營收為4,662萬美元，高於分析師預期的4,800萬美元。
Pharming Group Stock Up 3.1 %
輝瑞集團股價上漲3.1%
Institutional Investors Weigh In On Pharming Group
機構投資者看好Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Cowen Prime Advisors LLC lifted its holdings in Pharming Group (NASDAQ:PHAR – Get Rating) by 134.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,800 shares of the company's stock after acquiring an additional 8,500 shares during the period. Cowen Prime Advisors LLC's holdings in Pharming Group were worth $132,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.
一家機構投資者最近提高了對Pharming Group股票的頭寸。Cowen Prime Advisors LLC在提交給美國證券交易委員會的最近一份13F文件中稱，該公司在第四季度將其在製藥集團(納斯達克：PharGet Rating)的持股增加了134.9%。該基金持有14,800股該公司股票，在此期間又購買了8,500股。截至最近一個季度末，Cowen Prime Advisors LLC在Pharming Group持有的股份價值13.2萬美元。該公司0.03%的股份由機構投資者持有。
Pharming Group Company Profile
柏寧集團公司簡介
(Get Rating)
(獲取評級)
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
生物製藥公司Pharing Group N.V.開發蛋白質替代療法和精準藥物並將其商業化，用於治療美國、歐洲和國際上未得到滿足的罕見疾病和醫療需求。該公司的主導產品是Ruconest，一種用於治療急性遺傳性血管性水腫的重組人C1酯酶抑制劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- What to Expect from the Markets in a Recession
- MarketBeat: Week in Review 8/1 – 8/5
- 免費獲取StockNews.com關於Pharming Group的研究報告(Phar)
- 電動汽車可以推動美國鋁業股價走高
- 愛彼迎還能在經濟衰退中茁壯成長嗎？
- 康菲石油股價上漲，第二季度營收強勁
- 對衰退中的市場有什麼期待
- MarketBeat：回顧中的一週8/1-8/5
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharming Group Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pharming Group和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。